Conclusions
We found that the PD-L1 expression in the bone marrow megakaryocytes of
JAK2-mutated PMF patients was higher than the control group. This may
confirm the hypothesis that the oncogenic JAK2 mutation enhances the
PD-L1 promoter activity and its expression in JAK2 positive patients. We
hypothesize that patients with high PD-L1 expression may benefit from
checkpoint inhibitors, in combination with JAK2 inhibitors, in the
upfront setting of therapy.